167 related articles for article (PubMed ID: 29241756)
1. Gynecologic and andrologic dermatology and the metabolic syndrome.
Roth MM; Leader N; Kroumpouzos G
Clin Dermatol; 2018; 36(1):72-80. PubMed ID: 29241756
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
[TBL] [Abstract][Full Text] [Related]
3. Skin disease related to metabolic syndrome in women.
Misitzis A; Cunha PR; Kroumpouzos G
Int J Womens Dermatol; 2019 Sep; 5(4):205-212. PubMed ID: 31700973
[TBL] [Abstract][Full Text] [Related]
4. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
Housman E; Reynolds RV
J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
6. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.
Laaksonen DE; Niskanen L; Punnonen K; Nyyssönen K; Tuomainen TP; Valkonen VP; Salonen R; Salonen JT
Diabetes Care; 2004 May; 27(5):1036-41. PubMed ID: 15111517
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Syndrome During Menopause.
Mumusoglu S; Yildiz BO
Curr Vasc Pharmacol; 2019; 17(6):595-603. PubMed ID: 30179134
[TBL] [Abstract][Full Text] [Related]
8. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
Li L; Chen X; He Z; Zhao X; Huang L; Yang D
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
[TBL] [Abstract][Full Text] [Related]
9. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism.
Ozdemir S; Ozdemir M; Görkemli H; Kiyici A; Bodur S
Acta Obstet Gynecol Scand; 2010; 89(2):199-204. PubMed ID: 19900078
[TBL] [Abstract][Full Text] [Related]
10. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome.
Feldman RA; O'Neill K; Butts SF; Dokras A
Fertil Steril; 2017 Jan; 107(1):276-281. PubMed ID: 27842995
[TBL] [Abstract][Full Text] [Related]
11. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
Bhattacharya SM; Ghosh M; Basu R
J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
[TBL] [Abstract][Full Text] [Related]
12. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
13. Sex Hormone-Binding Globulin in Children and Adolescents.
Aydın B; Winters SJ
J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):1-12. PubMed ID: 26761949
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
[TBL] [Abstract][Full Text] [Related]
15. Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: The Healthy Twin Study.
Moon H; Choi I; Kim S; Ko H; Shin J; Lee K; Sung J; Song YM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):523-531. PubMed ID: 28581026
[TBL] [Abstract][Full Text] [Related]
16. Sex steroids and glucose metabolism.
Allan CA
Asian J Androl; 2014; 16(2):232-8. PubMed ID: 24457840
[TBL] [Abstract][Full Text] [Related]
17. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
[TBL] [Abstract][Full Text] [Related]
18. Endogenous Androgens and Sex Hormone-Binding Globulin in Women and Risk of Metabolic Syndrome and Type 2 Diabetes.
Fenske B; Kische H; Gross S; Wallaschofski H; Völzke H; Dörr M; Nauck M; Keevil BG; Brabant G; Haring R
J Clin Endocrinol Metab; 2015 Dec; 100(12):4595-603. PubMed ID: 26445113
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.
Gold DA; Reeder VJ; Mahan MG; Hamzavi IH
J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875
[TBL] [Abstract][Full Text] [Related]
20. Acne severity and the Global Acne Grading System in polycystic ovary syndrome.
Hacivelioglu S; Gungor AN; Gencer M; Uysal A; Hizli D; Koc E; Cosar E
Int J Gynaecol Obstet; 2013 Oct; 123(1):33-6. PubMed ID: 23948280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
